Recent Updates
Recently added Catalysts
AGEN Negative Sentiment Score: 20/100

AGENUS INC. (NASDAQ: AGEN) INVESTOR ALERT: Investors With Large Losses in Agenus Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Key Takeaway: A shareholder has filed a class action lawsuit against Agenus Inc. (NASDAQ: AGEN) on behalf of investors who purchased the company's securities between January 23, 2023, and July 17, 2024. The lawsuit alleges that Agenus made misrepresentations regarding its investigational therapy for metastatic colorectal cancer. Investors are advised that they can take legal action and that no fees or expenses will be incurred unless they participate in the litigation. Those interested in serving as a lead plaintiff must file by November 5, 2024.

Market Sentiment Analysis

CONCERNS & RISKS

  • Agenus is facing a securities class action lawsuit due to alleged misrepresentations.
  • The lawsuit concerns the development of Agenus' investigational therapy for metastatic colorectal cancer.
  • Investors with large losses are being alerted to consider legal actions against Agenus.

Full Press Release Details

NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Agenus Inc. (“Agenus” or the “Company”) (NASDAQ: AGEN) between January 23, 2023 and July 17, 2024, inclusive (the “Class Period”).
For more information, submit a form at Agenus Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or call us at (212) 951-2030.
According to the lawsuit, Agenus made misrepresentations concerning the development of the Company’s investigational therapy for the treatment of patients with metastatic colorectal cancer.
If you wish to serve as lead plaintiff for the Class, you must file papers by November 5, 2024. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
ATTORNEY ADVERTISING. © 2024 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Investor Relations Manager
Bernstein Liebhard LLP

Tags

class action lawsuit

Frequently Asked Questions

What is the class action lawsuit against Agenus Inc. about?

The lawsuit alleges misrepresentations by Agenus regarding its investigational therapy for metastatic colorectal cancer.

Who filed the securities class action lawsuit for Agenus Inc.?

Bernstein Liebhard LLP announced the lawsuit on behalf of investors who purchased Agenus securities.

What is the deadline to file as lead plaintiff in the Agenus lawsuit?

The deadline to file as lead plaintiff is November 5, 2024.

Do shareholders need to pay fees for representation in the lawsuit?

No, all representation is on a contingency fee basis, so shareholders pay no fees.

How successful has Bernstein Liebhard LLP been in class action cases?

Since 1993, the firm has recovered over $3.5 billion for clients and has significant litigation experience.

Last updated: Sep 9, 2024